| 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]- |
N,N'-二[{(5S)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-1,3-恶唑啉-5-基}甲基]苯基-1,2-二酰胺 |
1365267-36-2 |
| YH239-EE |
[N/A] |
1364488-67-4 |
| GNE 617 |
N-[[4-[(3,5-二氟苯基)磺酰基]苯基]甲基]咪唑并[1,2-A]吡啶-6-甲酰胺 |
1362154-70-8 |
| CarbaMic acid, N-[trans-4-[(diMethylaMino)Methyl]cyclohexyl]-, phenylMethyl ester |
苄基((1R,4R)-4 - ((二甲基氨基)甲基)环己基)氨基甲酸酯 |
1356953-43-9 |
| 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]- |
4-甲基-5-(2-(1,1,1-三氟-2-甲基丙-2-基)吡啶-4-基)噻唑-2-胺 |
1357476-69-7 |
| ML-228 |
KC7F2 |
1357171-62-0 |
| trans-4-((DiMethylaMino)Methyl)cyclohexanaMine diacetate |
(1R,4R)-4 - ((二甲基氨基)甲基)环己胺二乙酸酯 |
1356953-44-0 |
| ALK/IGF1R inhibitor |
AZD3463 |
1356962-20-3 |
| Mutant IDH1-IN-1 |
MUTANT IDH1-IN-1 |
1355326-21-4 |
| Aldose reductase-IN-1 |
1355612-71-3 |
1355612-71-3 |
| 5-chloro-4-[(3,4-dichlorophenoxy)Methyl]-2-fluoro-N-(Methylsulfonyl)benzaMide |
5-氯-4-[(3,4-二氯苯氧基)甲基]-2-氟-N-(甲基磺酰基)苯甲酰胺 |
1355631-24-1 |
| WEHI-345 |
N-[2-[4-氨基-3-(4-甲基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]-2-甲基丙基]-4-吡啶甲酰胺 |
1354825-58-3 |
| EW-7197 |
EW-7197 |
1352608-82-2 |
| MK5172 |
格佐匹韦 |
1350514-68-9 |
| FMoc-Val-Cit-PAB-MMAE |
FMOC-VAL-CIT-PAB-MMAE |
1350456-56-2 |
| XL765 |
XL765 |
1349796-36-6 |
| N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide |
化合物GSK503 |
1346572-63-1 |
| 1H-Indole-4-carboxaMide, 6-broMo-N-[(1,2-dihydro-4,6-diMethyl-2-oxo-3-pyridinyl)Methyl]-3-Methyl-1-[(1S)-1-Methylpropyl]- |
(S)-6-溴-1-(仲丁基)-N - ((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基 |
1346574-54-6 |
| S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide |
GSK126 |
1346574-57-9 |
| 1H-Indole-4-carboxaMide,6-broMo-N-[(1,2-dihydro-4,6-diMethyl-2-oxo-3-pyridinyl)Methyl]-3-Methyl-1-(1-Methylpropyl)- |
6-溴-1-(仲丁基)-N - ((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3- |
1346574-53-5 |
